Iconovo has announced that OINDP expert Gary Pitcairn will join the company as Senior Scientific Advisor to support development projects, particularly reformulation of drugs for inhalation. Pitcairn, who was most recently Chief Scientific Officer at Nanologica, previously headed respiratory groups at AstraZeneca, Mylan, Pfizer, and Pharmaceutical Profiles. He is also currently the chair of the Drug Delivery to the Lungs (DDL) conference scientific organizing committee.
The announcement says, “In this role Gary will give advice to the project teams working on reformulations and support the efforts in bringing in new CDMO projects to Iconovo. Reformulating known APIs, including biologics, for inhalation and/or new indications require deep scientific knowledge. By bringing in Gary to Iconovo we see that we can better serve research-based customers.”
Pitcairn commented, “I’m delighted to be joining the team at Iconovo. Developing new inhaled products is a challenging task, and Iconovo have both an impressive track record of device innovation and successful product development.”
Read the Iconovo press release.
